what could go wrong?, page-93

I have a question regarding the March 2014 presentation slide 12 or 13.

Phase II: 12 Weeks Improvement in Median PFS Is
Encouraging.


Progression Free Survival (PFS) of 5.2 vs. 2.4 months (p=0.017)

Hazard ratio for PFS of 0.56 (p=0.019)

Longer Time to Treatment Failure (4.0 months vs.
1.8 months) (p=0.007)

HA-Irinotecan patients treated for significantly
more cycles (six vs. two) (p=0.005)

No significant increase in toxicity was observed

I am ok with the above, but I am concerned about the p value of the two below.

Increase in DCR (76% vs. 46%, p=0.053)

Trend towards increased overall survival (10.1 vs. 8
months) (p=0.196)

Comments anyone?